COLUMN18(From left)Yuka Utsumi, Global Business Development Dept.; Keigo Baba, Legal Dept.; Steven Evans, Global Business Development Dept.Under the Fourth Medium-Term Plan, aiming to “Establish processes for providing product value in the global market,” Maruho is committed to maximizing product value and expanding business in China and the United States by contributing to the growth of local business through collaborations with local partners based on Maruho’s information provision capabilities. Today, the medical drug market is increasingly active in China in line with the steady growth of the economy. Farom Dry Syrup, an oral penem antibiotic being sold by our partner Beijing Golden Tang Medical Science & Technology Development Co., Ltd., and its subsidiaries since 2020, has acquired a strong reputation in the local market. It was included in China’s National Reimbursement Drug List (NRDL) in 2021.We were involved in the launch of a new global business in collaboration with our partners. Our goal is to establish a new development model capable of becoming a growth driver for Maruho in the future.In the U.S. market, Biofrontera Inc., a subsidiary of our partner Biofrontera AG, funded by Maruho in 2013, sells Xepi, a treatment for skin infections. Although growth is currently slowing due to the impact of COVID-19, we will continue to provide support for their sales promotion activities with the aim of further expanding sales and maximizing product value.Aiming to become a leading global company in dermatology, Maruho is striving to establish a global business model centering around three bases—Japan, the United States, and Europe. At the same time, in order to develop globally competitive human resources, Maruho assigns some of its employees to work in the United States and Europe. By increasing the number of personnel working overseas and establishing closer ties with partners, we will endeavor to expand our presence in the global market and enhance our business base.Developing a new business model for global developmentAs the environment surrounding prescription drugs is rapidly changing both in Japan and overseas, expectations for drugs that satisfy the unmet medical needs of patients are growing all over the world. Utilizing the exceptional information provision capabilities it has cultivated in Japan, Maruho aims to maximize product value by collaborating with partners and to contribute to better health for patients around the world.Establish processes for providing product value in the global marketGlobal PresenceContributing to better health for patients around the world in collaboration with partners overseas
元のページ ../index.html#20